Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA

K. G. Paulson, V. Voillet, M. S. McAfee, D. S. Hunter, F. D. Wagener, M. Perdicchio, W. J. Valente, S. J. Koelle, C. D. Church, N. Vandeven, H. Thomas, A. G. Colunga, J. G. Iyer, C. Yee, R. Kulikauskas, D. M. Koelle, R. H. Pierce, J. H. Bielas, P. D. Greenberg, S. Bhatia, R. Gottardo, P. Nghiem and A. G. Chapuis ()
Additional contact information
K. G. Paulson: University of Washington
V. Voillet: Fred Hutchinson Cancer Research Center
M. S. McAfee: Fred Hutchinson Cancer Research Center
D. S. Hunter: Fred Hutchinson Cancer Research Center
F. D. Wagener: Fred Hutchinson Cancer Research Center
M. Perdicchio: Fred Hutchinson Cancer Research Center
W. J. Valente: Fred Hutchinson Cancer Research Center
S. J. Koelle: University of Washington
C. D. Church: University of Washington
N. Vandeven: University of Washington
H. Thomas: University of Washington
A. G. Colunga: University of Washington
J. G. Iyer: University of Washington
C. Yee: MD Anderson Cancer Center
R. Kulikauskas: University of Washington
D. M. Koelle: University of Washington
R. H. Pierce: Fred Hutchinson Cancer Research Center
J. H. Bielas: University of Washington
P. D. Greenberg: University of Washington
S. Bhatia: University of Washington
R. Gottardo: University of Washington
P. Nghiem: University of Washington
A. G. Chapuis: University of Washington

Nature Communications, 2018, vol. 9, issue 1, 1-10

Abstract: Abstract Understanding mechanisms of late/acquired cancer immunotherapy resistance is critical to improve outcomes; cellular immunotherapy trials offer a means to probe complex tumor–immune interfaces through defined T cell/antigen interactions. We treated two patients with metastatic Merkel cell carcinoma with autologous Merkel cell polyomavirus specific CD8+ T cells and immune-checkpoint inhibitors. In both cases, dramatic remissions were associated with dense infiltration of activated CD8+s into the regressing tumors. However, late relapses developed at 22 and 18 months, respectively. Here we report single cell RNA sequencing identified dynamic transcriptional suppression of the specific HLA genes presenting the targeted viral epitope in the resistant tumor as a consequence of intense CD8-mediated immunologic pressure; this is distinguished from genetic HLA-loss by its reversibility with drugs. Transcriptional suppression of Class I loci may underlie resistance to other immunotherapies, including checkpoint inhibitors, and have implications for the design of improved immunotherapy treatments.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-06300-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-06300-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-06300-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().